SCHEMBL15569587

SCHEMBL15569587

O=C(CC(=O)C1CCOCC1)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
MAPT P10636 2/20 0.49
KMT2A Q03164 2/20 0.49
HRH3 Q9Y5N1 1/20 0.48
ERCC5 P28715 1/20 0.47
FEN1 P39748 1/20 0.47
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
GSK3B P49841 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PHGDH O43175 2/20 0.44
CCR2 P41597 1/20 0.43
HTR1A P08908 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
KCNH2 Q12809 1/20 0.43
CD274 Q9NZQ7 1/20 0.43
P2RX7 Q99572 1/20 0.41
LMNA P02545 1/20 0.41
ACKR3 P25106 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19806639 0.89 ERCC5 (0.55) ALDH1A1MAPTKMT2AERCC5FEN1
SCHEMBL12186012 0.81 ERCC5 (0.47) MAPTKMT2AERCC5FEN1GSK3B
SCHEMBL15569958 0.77 RAB9A (0.40) ALDH1A1MAPTKMT2AHRH3ERCC5
SCHEMBL15568069 0.77 RAB9A (0.40) ALDH1A1MAPTKMT2AHRH3ERCC5
SCHEMBL15568068 0.77 RAB9A (0.40) ALDH1A1MAPTKMT2AHRH3ERCC5
SCHEMBL15568071 0.77 RAB9A (0.40) ALDH1A1MAPTKMT2AHRH3ERCC5
SCHEMBL15568984 0.75 ERCC5 (0.44) ALDH1A1MAPTKMT2AERCC5FEN1
SCHEMBL6981291 0.74 MGLL (0.70) MAPTKMT2AMEN1
SCHEMBL30724425 0.73 PIK3CD (0.34) HDAC1HDAC2SMN1; SMN2
SCHEMBL600674 0.73 ERCC5 (0.72) ALDH1A1MAPTKMT2AERCC5FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2885293-B1 SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS JANSSEN PHARMACEUTICA NV (BE) 2016-07-27 EP disclosed
EP-2885293-A1 SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS Janssen Pharmaceutica, N.V. (BE) 2015-06-24 EP disclosed
US-8901314-B2 Substituted pyrazoles as N-type calcium channel blockers JANSSEN PHARMACEUTICA NV (BE) 2014-12-02 US disclosed
US-20140163031-A1 SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS JANSSEN PHARMACEUTICA NV (BE) 2014-06-12 US disclosed
WO-2014028803-A1 SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS JANSSEN PHARMACEUTICA NV (BE) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163031-A1 SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS CACNA1B, CACNA1E, CACNA1A ALDH1A1 3178/4885MAPT 3284/4885KMT2A 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.